EcoR1 Puts Up Big Gains as the Hedge Fund Scoops Up Biotech

EcoR1’s main hedge fund has produced big, double-digit gains in 2019, according to a document obtained by Institutional Investor.

Steve Taub December 22, 2019

Illustration by II

EcoR1 Capital is on a buying spree of beaten-down, biotechnology companies as it nears the end of 2019 with big returns.In November, the hedge fund firm established sizable stakes in Pieris Pharmaceuticals, AnaptysBio, and X4 Pharmaceuticals, according to regulatory filings. This month,

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

develop build:2025-12-18 Login